Mind Cure Health Focuses On Research Into Psychedelics For Traumatic Brain Injury

Mind Cure Health (CSE: MCUR) as of this morning has seen the transition of one of its advisory board members to that of primary investigator consultant. Dr Dan Engle will be transitioning to the new role, as the company begins focusing on its research into the treatment of traumatic brain injury with psychedelics.

Originally appointed to the firms advisory board back in the fall of 2020, Engle is board certified in psychiatry and neurology. He currently operates a clinical practice that is focused on combining functional medicine with integrative psychiatry and neuro-cognitive restoration.

Now, he will be leading Mind Cure’s research into traumatic brain injury, which has been marked as being a priority indication by the company due to it sharing biological pathways associated with pain. As a result, the company will be researching the therapeutic potential of psychedelic compounds for such injuries and related conditions, with Engle tasked with moving the research from pre-clinical to the clinical stage.

Based on a study conducted in 2017, it has been reported that the amount of traumatic brain injuries in North America increased by 53% from 2006 to 2014. Such injuries can have effects lasting anywhere from a few days to a lifetime, with an average of 32,000 people in the US dying each day from injuries that include such indications.

“Mind Cure is fortunate that Dr. Engle has chosen to bring his expertise and clinical experience with trauma and head injury to lead Mind Cure’s research efforts. Dr. Engle is a trusted resource whose guidance will be pivotal in leading this transformative research program. TBI issues not only affect individuals but also can have lasting effects on families and communities.”

Kelsey Ramsden, CEO

Mind Cure Health last traded at $0.63 on the CSE.

FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply